Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd. clinical trials

A subsidiary of Fosun Pharma

The registry lists 32 studies whose lead sponsor is Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd.. 19 are recruiting or about to start. Per ClinicalTrials.gov, last updated Oct 15, 2026.

Studies

Recruiting first, then most recently updated. Showing 32 of 32. All Fosun Pharma studies →

• A Phase II Clinical Trial to Evaluate the Efficacy and Safety of FXS5626 in Patients With NIURecruitingNCT07552012Phase 2

  Sponsor listed in the registry: Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd.

• Phase I Study of FXS0683 in the Treatment of Blood TumorsRecruitingNCT07616089Phase 1

  Sponsor listed in the registry: Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd.

• QT Interval Effects Study of Oral FXS5626 TabletsRecruitingNCT07695779Phase 1

  Sponsor listed in the registry: Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd.

• Mass Balance Study of [¹⁴C]FXS4640 in Healthy Adult MalesNot yet recruitingNCT07872579Phase 1

  Sponsor listed in the registry: Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd.

• A Study of XS-04 in Patients With Relapsed or Refractory Hematologic MalignanciesRecruitingNCT06820268Phase 1

  Sponsor listed in the registry: Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd.

• XS-03 in Combination With FOLFOX or FOLFIRI and Bevacizumab for Treatment of Metastatic Colorectal Cancer Patients With RAS MutationEnrolling by invitationNCT06936527Phase 1/2

  Sponsor listed in the registry: Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd.

• A Multicenter, Open-label Study Evaluating the Long-term Safety and Efficacy of XH-S003 Capsules in Patients With Paroxysmal Nocturnal HemoglobinuriaEnrolling by invitationNCT07657052Not applicable

  Sponsor listed in the registry: Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd.

• Phase II/III Study of FXS5626 in Participants With Non-segmental VitiligoNot yet recruitingNCT07840820Phase 2/3

  Sponsor listed in the registry: Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd.

• A Phase 2 Study of Luvometinib Combined With Anlotinib in KRAS-mutated NSCLCRecruitingNCT07562581Phase 2

  Sponsor listed in the registry: Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd.

• FXS6837 for the Treatment for IgAN Patients（Longterm Study）Not yet recruitingNCT07750665Phase 2

  Sponsor listed in the registry: Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd.

• A Study of the Efficacy and Safety of FXS6837 Capsules Compared to Eculizumab for 24 Weeks in Patients With PNH.Not yet recruitingNCT07747090Phase 3

  Sponsor listed in the registry: Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd.

• Phase Ia/Ib Study of FXB0871 Monotherapy in Locally Advanced/Metastatic Solid TumorsNot yet recruitingNCT07558200Phase 1

  Sponsor listed in the registry: Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd.

• FXS6837 for the Treatment of IgAN PatientsNot yet recruitingNCT07502638Phase 2

  Sponsor listed in the registry: Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd.

• Phase I Study of FXS887 in the Treatment of Solid TumorsNot yet recruitingNCT07345637Phase 1

  Sponsor listed in the registry: Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd.

• Follow-up Study to Evaluate the Safety and Efficacy of FCN-159 in Pediatric Participants With Neurofibromatosis Type 1Not yet recruitingNCT07024394Phase 1/2

  Sponsor listed in the registry: Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd.

• FCN-159 Monotherapy Versus Chemotherapy by Investigator's Choice in Pediatric Low-grade Glioma Patients With BRAF AlterationNot yet recruitingNCT07004075Phase 3

  Sponsor listed in the registry: Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd.

• To Evaluate the Efficacy, Safety, and PK Characteristics of FCN-159 in Pediatric Patients With Refractory/Recurrent LCHRecruitingNCT05997602Phase 2

  Sponsor listed in the registry: Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd.

• FS-1502 Versus T-DM1 for HER2-Positive Unresectable Locally Advanced or Metastatic Breast CancerRecruitingNCT05755048Phase 3

  Sponsor listed in the registry: Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd.

• A Phase I/II Clinical Study of SAF-189s in Non-small Cell Lung Cancer (NSCLC) PatientsRecruitingNCT04237805Phase 1/2

  Sponsor listed in the registry: Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd.

• A Phase 1 Study of XH-S003 in Healthy VolunteersCompletedNCT05946876Phase 1

  Sponsor listed in the registry: Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd.

• A Phase I Study of XH-S004 in Healthy VolunteersCompletedNCT06236841Phase 1

  Sponsor listed in the registry: Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd.

• Study of XH-S003 in Healthy VolunteersCompletedNCT06272747Phase 1

  Sponsor listed in the registry: Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd.

• A Multicenter, Randomized, Double-blind, Placebo-controlled Parallel-group Phase 2 Clinical Trial to Evaluate the Efficacy and Safety of XH-S004 Tablets in Patients With Non-cystic Fibrosis BronchiectasisActive, not recruitingNCT06981091Phase 2

  Sponsor listed in the registry: Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd.

• The Phase Ib Clinical Trial of the XH-S004 Tablet in Patients With Chronic Obstructive Pulmonary Disease (COPD) to Evaluate Its Safety, Tolerability, Pharmacokinetic Characteristics and Pharmacodynamic Characteristics After Multiple AdministrationsActive, not recruitingNCT07035652Phase 1

  Sponsor listed in the registry: Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd.

• A Phase IIa Study in Primary IgA Nephropathy PatientsCompletedNCT07634744Phase 2

  Sponsor listed in the registry: Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd.

• Phase 1 Study of FS-1502 in Patients With HER2 Expressed Advanced Solid Tumors and Breast Cancer.CompletedNCT03944499Phase 1

  Sponsor listed in the registry: Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd.

• FCN-159 in Adult Patients With Symptomatic, Inoperable Neurofibromatosis Type 1-Related Plexiform NeurofibromasActive, not recruitingNCT05913037Phase 3

  Sponsor listed in the registry: Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd.

• FCN-338 in Combination With Azacitidine or Chemotherapy in Myeloid NeoplasmsActive, not recruitingNCT06858618Phase 2

  Sponsor listed in the registry: Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd.

• Study to Evaluate the Safety, Tolerability, PK Characteristics and Anti-tumor Activity of FCN-159 in Adult and Pediatric Participants With Neurofibromatosis Type 1Active, not recruitingNCT04954001Phase 1/2

  Sponsor listed in the registry: Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd.

• Study Of Comparing SAF-189s With Crizotinib In First Line ALK-Positive Advanced and Metastatic NSCLCActive, not recruitingNCT06569420Phase 3

  Sponsor listed in the registry: Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd.

• MEK Inhibitor FCN-159 To Treat Advanced Melanoma With NRAS-aberrant (Ia) and NRAS-mutant (Ib)or NF1-mutant(1b)SuspendedNCT03932253Phase 1

  Sponsor listed in the registry: Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd.

• A Phase 1 Study to Evaluate FN-1501 Monotherapy in Patients With Advanced Solid Tumors and R/R AMLTerminatedNCT03690154Phase 1

  Sponsor listed in the registry: Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd.